The validation process, whereby the relevance and reliability of a test or testing strategy are independently evaluated, has reached the point at which it is imperative that some important decisions are taken, if the protection of human health and of the general environment is to be improved, and if the biological efficacy of various products is to be assured.
Firstly, it is unlikely that there will be many further examples of the direct replacement of an animal test by a non-animal test, as has been possible, for example, with skin corrosivity testing. Dealing with target organ and system toxicity, and with complex phenomena such as carcinogenicity and reproductive toxicity, will require batteries of tests, which will need to be used intelligently, selectively and in stepwise testing strategies, in order to provide information of various kinds, which can be incorporated into novel procedures for hazard identification and risk assessment. Both the individual components of these batteries and their strategic use will need to be validated. 1 Secondly, while the validation process has been shown to be effective when the ECVAM/ICC-VAM/OECD principles are applied to in vitro systems for the testing of both chemicals and some biological products, how these principles should be applied in the independent evaluation of in silico procedures, including the application of (Q)SAR and expert systems, still has to be clarified.
Thirdly, and most ominously, the internationally agreed ECVAM/ICCVAM/OECD validation principles are under threat, because of pressure from vested interests. For example, the OECD and some regulatory agencies appear to have sought to circumvent these principles in order to secure the acceptance of animal tests for endocrine disruptors, on the basis of so-called validation studies on methods which do not satisfy the agreed criteria for test development, validation, independent assessment and unbiased peer review. 2, 3 We are impressed by the efforts of ECVAM to make the practical validation process as efficient and straightforward as possible, 4 and by the efforts of the EC and the OECD to deal with the validation of in silico procedures, 5 but we must look to ECVAM and ICCVAM to take urgent action to prevent the acceptance of (and consequent regulatory insistence on the application of) animal tests for endocrine disruptors which have not been independently shown to be relevant and reliable. This issue of ATLA contains two more of our own contributions to the debate on these issues. Firstly, we have discussed the validation and acceptance of intelligent testing strategies involving (Q)SAR modelling, read-across and other non-animal approaches, 6 and secondly, we have spelled out the need for an invalidation process, to parallel and protect the validation process by providing a means whereby currently-accepted animal tests and candidate animal and non-animals tests, which do not, and could never, satisfy the criteria for necessity, test development, prevalidation, validation and acceptance, could be independently reviewed and could then be declared invalid, i.e. irrelevant and unreliable for their claimed purposes. 7 In the interests of securing a sound basis for tackling the great challenges before us all, including the introduction of the EU REACH system, we invite comments on these issues, as well as on our own suggestions, for publication in future issues of ATLA.
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